Investment Thesis
IR-Med is a distressed medical device company with severe structural insolvency, negative stockholders' equity of -$625K, and catastrophic revenue collapse of -115% YoY alongside -$1.5M net losses. The company is cash flow negative with operating cash burn of -$181K, critically low liquidity (0.12x current ratio), and minimal cash reserves ($63K) that cannot sustain operations or service $800K in liabilities.
Strengths
- Minimal capital expenditure requirements suggest low ongoing infrastructure costs
- Some operational focus in medical device sector with regulatory barriers to entry
Risks
- Negative stockholders' equity indicates technical insolvency with liabilities exceeding assets by $625K
- Revenue essentially eliminated (-115% YoY) with only -$3K revenue in latest period indicating operational collapse
- Severe liquidity crisis with current ratio of 0.12x and only $63K cash against $800K total liabilities
- Persistent net losses of -$1.5M with negative operating cash flow of -$181K unsustainable without external capital injection
- Zero insider trading activity in 90 days suggests management has abandoned ship
Key Metrics to Watch
- Cash balance trajectory and runway
- Ability to reverse revenue decline or achieve strategic acquisition/recapitalization
- Quarterly burn rate and path to liquidity event or bankruptcy filing
- Debt restructuring or equity raise announcements
Financial Metrics
Revenue
-3.0K
Net Income
-1.5M
EPS (Diluted)
$-0.02
Free Cash Flow
-183.0K
Total Assets
175.0K
Cash
63.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
17,966.7%
Net Margin
49,133.3%
ROE
N/A
ROA
-842.3%
FCF Margin
6,100.0%
Balance Sheet & Liquidity
Current Ratio
0.12x
Quick Ratio
0.12x
Debt/Equity
N/A
Debt/Assets
457.1%
Interest Coverage
N/A
Long-term Debt
13.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-29T13:38:11.957319 |
Data as of: 2025-06-30 |
Powered by Claude AI